Trimetazidine Hydrochloride is the new twice-daily formulation of the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients. Trimetazidine inhibits fatty acid pathway by inhibiting 3-ketoacylCoA thiolase enzyme and transfers oxygen to glucose pathway.Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heat more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.
Presntation:
Metacard MR Tablet: Each modified release tablet contains Trimetazidine Hydrochloride BP 35 mg.
Indications:
Metacard MR Tablet is a metabolic treatment for ischaemic heart disease. It can be used at all stages of angina pectoris and in post myocardial infarction. Metacard MR therapy has also demonstrated beneficial effects when administered during bypass surgery.
Dosage & Administration:
The recommended dose of Metacard MR (Trimetazidine) is 35 mg twice daily or 20 mg tablet thrice daily during meals. The benefit of the treatment should be assessed after three months and Trimetazidine should be discontinued if there is no treatment response
Metacard MR Tablet: Each modified release tablet contains Trimetazidine Hydrochloride BP 35 mg.
Metacard MR Tablet is a metabolic treatment for ischaemic heart disease. It can be used at all stages of angina pectoris and in post myocardial infarction. Metacard MR therapy has also demonstrated beneficial effects when administered during bypass surgery.
One tablet at mealtimes in the morning and evening.
Trimetazidine is contraindicated in-patients with a known hypersensitivity to its components.
Trimetazidine is safe and well tolerated. Rare cases of gastrointestinal disorders, nausea & vomiting have been reported.
No drug interactions so far have been reported. In particular, no interactions have been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidaemic agents or digitalis preparation.
Use in Pregnancy: Studies in animals have not demonstrated teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.
Use in Lactation: In the absence of data, breastfeeding is not recommended during treatment.
Metacard MR Tablet: Each box contains 70's tablets in blister pack.
FR
DE
